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Abstract. Enterochromaffin-like (ECL) tumors are documented in pa-
tients with hypergastrinemia secondary to chronic atrophic gastritis or
with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1
(ZES-MEN-1). In patients with ECL tumors and atrophic gastritis, nor-
mogastrinemia after antrectomy has resulted in resolution, regression, or
stabilization of ECL tumors. The natural history of ECL tumors associated
with ZES-MEN-1 following normalization of gastrin levels after gastri-
noma resection has not been previously reported. The purpose of this study
was to determine the course of ECL tumors in patients with ZES-MEN-1
following normalization of serum gastrin levels after gastrinoma resection.
Two patients with ZES-MEN-1 had biopsy-proven ECL tumors on endo-
scopic evaluation. They then underwent surgical exploration that included
distal pancreatectomy, enucleation of pancreatic head tumors, duode-
notomy with excision of submucosal tumors, and peripancreatic lymphad-
enectomy. Gastric ECL tumors larger than 1.0 cm were locally excised. Pa-
tients underwent long-term follow-up with biochemical and endoscopic
surveillance. Normogastrinemia was achieved and sustained following gas-
trinoma resection in two patients with ZES-MEN-1. Periodic endoscopic
surveillance over a 6-year period showed complete resolution of the ECL
tumors. The development of ECL tumors associated with ZES-MEN-1 is
multifactorial. Studies identified a genetic influence on tumor growth with
loss of heterozygosity at the MEN-1 gene locus in ECL tumors. The reso-
lution of ECL tumors in ZES-MEN-1 patients who are normogastrinemic
indicates that an elevated gastrin level is a primary initiator for develop-
ment of these tumors. Therefore both genetic defects and hypergastrinemia
are causative agents. Normalization of serum gastrin levels is critical for
the prevention of aggressive forms of ECL tumors.
Enterochromaffin-like (ECL) tumors are primarily documented in
patients with hypergastrinemia; they are secondary to chronic atro-
phic gastritis or are seen in patients with the Zollinger-Ellison syn-
drome (ZES) and multiple endocrine neoplasia type 1 (MEN-1)
[1]. These endocrine cell neoplasms are frequently referred to as
multiple gastric carcinoids in both conditions. Hyperplasia of the
ECL cells, as well as tumors, develop primarily as the result of the
trophic effect of chronic hypergastrinemia on all of the neuroendo-
crine cells of the proximal stomach.
A literature review of 224 ECL tumors found them to be associ-
ated with chronic atrophic gastritis in 79% of patients; 10% of pa-
tients had ZES, and 11% were sporadic [1]. The sporadic tumors
were solitary, and they were larger and more biologically aggressive
than those that are gastrin-dependent. Of patients with ZES, 92%
had documented MEN-1. The incidence of ECL tumors in ZES-
MEN-1 patients may be as high as 30%, compared to 5% in patients
with chronic atrophic gastritis and hypergastrinemia [2–5]. Because
of the rarity of ECL tumors in sporadic cases of ZES, a genetic
factor related to the gene mutation has been considered an impor-
tant contributing, if not primary, cause of their occurrence in
MEN-1 patients.
In patients with ECL tumors, atrophic gastritis, and hypergas-
trinemia, normogastrinemia after antrectomy has resulted in reso-
lution, regression, or stabilization of ECL tumors [6–8]. The natu-
ral history of ECL tumors in ZES-MEN-1 patients following
normalization of gastrin levels after gastrinoma resection has not
been previously reported. We report two patients with ZES-
MEN-1 and ECL tumors who underwent operative treatment for
their gastrinomas resulting in normalization of gastrin levels. We
also document the effect on the remaining ECL tumors.
Patients and Methods
Two patients with ZES-MEN-1 had biopsy-proven ECL tumors on
endoscopic evaluation. Endoscopic evaluation was performed for
surveillance and diagnostic purposes. Smaller tumors were not
completely excised because of their extent. Both patients then un-
derwent surgical exploration that included distal pancreatectomy,
enucleation of pancreatic head tumors, duodenotomy with excision
of submucosal tumors, and peripancreatic lymphadenectomy. Gas-
tric ECL tumors larger than 1.0 cm were locally excised. All pa-
tients were then followed biochemically and with endoscopic sur-
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A 39-year-old woman was admitted to the University of Michigan
Hospital in August 1996 with hypercalcemia and symptomatic hy-
poglycemia. Two months prior to admission she became confused,
and laboratory studies revealed a blood glucose level of 50 mg/dl
and a serum calcium level of 11.7 mg/dl. Her fasting blood glucose
was 50 mg/dl, the intact parathyroid hormone level (iPTH) was 826
pg/ml (10–65 pg/ml), and the prolactin level was 173 ng/ml (< 32
ng/ml). Magnetic resonance imaging (MRI) did not demonstrate a
pituitary tumor. Increasing symptoms of hypoglycemia with blood
glucose levels as low as 20 mg/dl and a diagnosis of MEN-1
prompted an urgent referral for treatment.
The patient had a history of nephrolithiasis, amenorrhea, and
galactorrhea. She denied a history of diarrhea or peptic ulcer dis-
ease but had esophageal reflux symptoms for which she had been
taking omeprazole daily during the past year. There was no family
history of MEN-1.
The admission laboratory studies included the following: serum
calcium 12.6 mg/dl, serum insulin 66 IU/ml, and blood glucose 20
mg/dl with an insulin/glucose ratio of 3.3. The serum gastrin was
1179 pg/ml (30–115 pg/ml). Serum glucagon (145 pg/ml) and so-
matostatin (170 pg/ml) were within the normal range. An abdomi-
nal computed tomography (CT) scan showed two pancreatic tu-
mors in the body of the pancreas (5 × 5 cm and 2 × 2 cm), a normal
liver, hypertrophic gastric rugae, and a 1.5 cm submucosal gastric
lesion consistent with an ECL tumor (Fig. 1).
With a diagnosis of MEN-1 hyperparathyroidism (HPT), hyper-
insulinism, and hypergastrinemia, she was taken to the operating
room 2 days after admission. The initial procedure was subtotal
parathyroidectomy and cervical thymectomy, excising all parathy-
roid tissue except a viable 60 mg remnant. In all, 8.8 g of hyperplas-
tic parathyroid tissue was excised. During the abdominal explora-
tion, distal pancreatectomy and splenectomy were performed. A 1
cm neuroendocrine tumor was enucleated from the head of the
pancreas. Four neuroendocrine tumors, all less than 0.5 cm in di-
ameter, were excised through a vertical duodenotomy. Regional
lymph nodes were excised. Several tumors were palpable in the car-
dia of the stomach. The two largest, measuring 1.5 and 1.0 cm in
diameter, respectively, were locally excised through a small gas-
trotomy (Fig. 2). Frozen section studies confirmed the diagnosis of
neuroendocrine tumors and negative lymph node involvement. On
immunohistochemical studies, the two large pancreatic tumors in
the body stained positive for insulin, and the four tumors in the
duodenum stained positive for gastrin. The gastric ECL tumors
stained for neuron-specific enolase and chromogranin A.
The patient’s postoperative course was uneventful, except for
her serum calcium level reaching a nadir of 7.1 mg/dl on postopera-
tive day (POD) 1. At this time the serum gastrin level was 317 pg/
ml, and on POD 5 it was 216 pg/ml. Both of these levels were ob-
tained while the patient was on intravenous H2-blockade. Calcium
levels were normalized by POD 6 with supplemental oral calcium
Fig. 1. Case 1. Abdominal computed tomography (CT) scan. Small arrow
points to polypoid lesion [enterochromaffin-like (ECL) tumor] along the
greater curvature of the stomach. Note the hypertrophic gastric mucosal
folds typically seen in patients with Zollinger-Ellison syndrome. Large ar-
row points to 5.5 cm neuroendocrine tumor (insulinoma) arising from the
pancreatic body.
Fig. 2. Artist’s rendition of operative findings in case 1 and the surgical
procedures performed. The duodenal gastrinomas were neither seen nor
palpated until the duodenum was opened. The operation included distal
pancreatectomy and splenectomy, enucleation of a neuroendocrine tumor
in the pancreatic head, duodenotomy, and excision of four submucosal
gastrinomas. The two largest ECL tumors were excised through a small
gastrotomy. A regional peripancreatic lymph node dissection was per-
formed.
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and vitamin D. Bromocriptine was started prior to discharge, and
her prolactin level was 43 pg/ml within 2 weeks. An iPTH level at 3
weeks after operation was 32 pg/ml, and her serum calcium at this
time was 9.7 mg/dl. The oral calcium was discontinued in April
1997, and all subsequent serum calcium levels have been within the
normal range. At 6 months after operation, endoscopic examina-
tion with gastric biopsy showed evidence of some persistent neuro-
endocrine hyperplasia and small subcutaneous nodules. By July
1997 there were no ECL tumors present, and the mucosa appeared
normal on endoscopy. Her serum gastrin level was normal at this
time. Her most recent endoscopic evaluation, performed in Sep-
tember 2001, showed no evidence of recurrent disease. In March
2002 the patient remains asymptomatic.
Case 2
A 55-year-old woman was admitted to the University of Michigan
Medical Center in February 1995 with a diagnosis of HPT and ZES.
Her family history was strongly positive for the MEN-1 syndrome,
with a sister having HPT and ZES (1992), a niece with HPT and a
pituitary tumor (1994), and a nephew with HPT (1994). Although
she had a vague history of intermittent “upset stomach,” there was
no history of diarrhea or proven peptic ulcer disease. She was on no
medications. The patient had undergone a previous secretin stimu-
lation test. At that time her baseline serum gastrin level was 200
pg/ml (normal < 100 pg/ml); it increased to 654 pg/ml at 2 minutes
and 736 pg/ml at 5 minutes after secretin stimulation. Her pancre-
atic polypeptide level was 2090 pg/ml. The serum calcium levels
ranged from 11.2 to 12.0 mg/dl and iPTH levels from 300 to 333
pg/ml (normal 10–65 pg/ml) during the previous 6 months. The se-
rum prolactin level was elevated, at 50.4 ng/ml (normal 3.3–26.7
ng/ml). An endoscopic ultrasound scan revealed a 0.6 cm neuroen-
docrine tumor in the pancreatic neck and two submucosal lesions
estimated to be 1.0 to 1.5 cm in diameter in the proximal cardia of
the stomach, as well as multiple smaller submucosal lesions.
In February 1995 the patient underwent subtotal parathyroidec-
tomy and cervical thymectomy. A 60-mg viable remnant of an infe-
rior gland was preserved after excising 2.4 g of hyperplastic para-
thyroid tissue. Her serum calcium level reached a nadir of 6.1 mg/dl
while receiving oral calcium and dihydrotachysterol (DHT) during
the early postoperative period. An octreotide scan was obtained on
POD 1. There were no foci of uptake in the pancreas, liver, or other
locations. She was discharged from the hospital on POD 3.
The patient was readmitted the following month for pancreati-
coduodenal exploration. At operation, several additional small
neuroendocrine tumors were palpable in the pancreatic body and
tail, and distal pancreatectomy was performed. The pancreatic
head and uncinate process were normal to palpation. Intraopera-
tive ultrasonography did not identify any pancreatic lesions. Three
submucosal neuroendocrine tumors, each less than 0.5 cm, were
locally excised from the second and third parts of the duodenum
through a vertical duodenotomy. Regional peripancreatic and duo-
denal lymph nodes were negative on frozen section examination for
metastatic disease. Two neuroendocrine tumors were locally ex-
cised from the gastric cardia through a small gastrotomy (Fig. 3).
Immunohistochemical studies demonstrated positive staining for
gastrin in the three duodenal tumors. The three pancreatic tumors
ranged in size from 0.8 to 0.9 cm. Two of these tumors stained posi-
tive for glucagon, and one was focally positive for serotonin. The
gastric neuroendocrine tumors stained negative for gastroenteric
hormones. On POD 1, her serum gastrin was 48 pg/ml. She was
discharged 11 days later without complications.
In August 1995, her serum calcium was 9.8 mg/dl and the IPTH
was 18 mg/dl (normal 10–65 mg/dl). The DHT and oral calcium
were discontinued. A serum gastrin level was 60 pg/ml. Endoscopy
at this time revealed no gross tumors in the stomach, although ran-
dom biopsies showed neuroendocrine cell hyperplasia staining
positive for chromogranin A and focally for serotonin.
During the follow-up, the patient has continued to have normal
serum gastrin levels. An endoscopic examination in July 1997 re-
vealed no abnormalities except a 1 cm nodule in the cardia, which
on biopsy was found to be lymphoid hyperplasia. No neuroendo-
crine tumors were noted on random biopsies. In May 1998, her se-
rum gastrin level was 61 pg/ml (normal < 200 pg/ml), calcium level
was 9.5 mg/dl (normal 8.4–10.2 mg/dl), iPTH was 2.8 pmol/L (1.3–
7.6 pmol/L), and the prolactin level was 14.0 ng/ml (normal 3.0–
32.0 ng/ml) on bromocriptine. However, in March 2002 her serum
calcium was 10.9 mg/dl, and the iPTH was 77 mg/dl (normal 10–65
mg/dl). Her serum gastrin at this time was 89 pg/ml. Yearly endo-
scopic evaluations have revealed no evidence of recurrent ECL tu-
mors.
Fig. 3. Artist’s rendition of operative findings in case 2 and the surgical
procedures performed. There were no neuroendocrine tumors in the pan-
creatic head or uncinate process. Three submucosal duodenal gastrinomas
were locally excised, being first palpated only after a duodenotomy. Re-
gional lymph node dissection revealed no metastases. Two palpable ECL
tumors were locally excised through a gastrotomy.
654 World J. Surg. Vol. 28, No. 7, July 2004
Discussion
The first report of an ECL tumor in conjunction with ZES-MEN-1
was by Carney et al. in 1983 [9]. Since that time, approximately 50
ECL tumors in conjunction with confirmed ZES-MEN-1 have
been reported in the English literature [1, 10–15]. The pathophysi-
ology of the development of ECL tumors in patients with MEN-1
appears to be multifactorial, attributed to a combination of genetic
and environmental influences.
Pathophysiology
Enterochromaffin-like tumors are also referred to as ECLomas,
gastric argyrophilic carcinoids, and ECL cell carcinoids. The term
“gastric carcinoid” may apply to cells originating from other endo-
crine cell types. However, most stem from ECL cells, which contain
histamine and are located in the gastric oxyntic mucosa. The term
“enterochromaffin-like” was first introduced by Hakanson et al. in
1967 and was used in reference to a specific cell type by Capella et
al. in 1969 [16, 17]. There are seven endocrine cell types in human
gastric mucosa, each of which secretes one main product. The ECL
cells are the predominant endocrine cell, comprising 30% to 45%
of the total endocrine cell mass in normal patients and 65% of the
cell mass in patients with ZES [18–20]. It has been shown that gas-
trin principally stimulates ECL cells to secrete histamine, which in
turn stimulates the parietal cells to secrete acid [21, 22]. It was pre-
viously thought that gastrin primarily stimulated the parietal cells
directly to secrete acid. In addition to the secretory effects of gas-
trin on ECL cells there is also a trophic effect on these cells [23].
Although the hypergastrinemia can promote hypertrophy and hy-
perplasia of ECL cells, it has not been shown that hypergastrinemia
can induce transformation of hyperplasia into ECL tumors [24].
However, many believe that the gastrin-induced trophic effect may
be responsible for the development of ECL tumors. Hypertrophy
and hyperplasia can be prevented with ECL gastrin-receptor block-
ade and decreased hypergastrinemia [25, 26]. Some investigators
found that the duration of hypergastrinemia correlated with the
amount of ECL cell proliferation [27, 28]. Others have reported no
increase in ECL density over time in the presence of a stable gastrin
level [20]. This difference may be secondary to variations in serum
gastrin levels. In patients with normal or mildly elevated gastrin
levels, there is no relation between serum gastrin levels and ECL
cell density [29, 30]. In patients with more severe hypergastrinemia
(serum gastrin > 400 pg/ml), there were significant increases in
ECL cell density [31].
The ECL cell density has also been shown to differ between the
sexes. ECL cell density is increased in women with ZES [2, 32], and
women do not display reductions in the ECL density with aging, as
is seen in men [30]. Interestingly, two-thirds of gastrin-dependent
ECL tumors occur in women, and 80% of sporadic ECL tumors
occur in men [1, 31].
The spectrum of ECL cell histopathology ranges from hyperpla-
sia to invasive tumors. Rindi [33] described three distinct types of
ECL tumors that depended on the patient’s clinical history [30].
Type I tumors are associated with chronic atrophic gastritis and
hypergastrinemia. Type II tumors are associated with hypertrophic
gastropathy, as seen in ZES. Type I and II tumors are multicentric,
are confined to the mucosa and submucosa, and rarely metastasize.
The incidence of metastatic disease is 7% to 12% for gastrin-
dependent (types I and II) ECL tumors [1]. If metastatic, they
spread to local lymph nodes and rarely to the liver. Type III tumors
are sporadic and solitary, and they occur in patients who have either
normal or mild nonatrophic gastritis. They are the only type that is
generally not associated with hypergastrinemia. Interestingly, a
study of five patients with type III tumors found a 100% incidence
of Helicobacter pylori infection [34]. The patients with the gastric
carcinoid tumors were also found to have serum gastrin levels
higher than those in patients with gastric and duodenal ulcers and
associated H. pylori infections, yet lower than in those with chronic
atrophic gastritis. The authors postulated that H. pylori infection
may lead to mucosal atrophy and subsequent hypergastrinemia.
Sporadic tumors also tend to contain different endocrine cell
types rather than ECL cells alone. Type III tumors are larger and
more invasive, and the patients may have carcinoid symptoms. The
median size of type III tumors is 2 cm in contrast to median sizes of
0.7 cm and 0.5 cm for type I and II tumors [1]. In a review of type 3
tumors, 80% had lymphoinvasion and 30% angioinvasion [31].
Metastatic disease was to the lymph nodes in 20% and to the liver in
40% to 52% of patients with type III tumors [1]. Until recently, type
III tumors were the only type with tumor-related mortality.
Bordi et al. reported two patients with ZES-MEN-1 who died 4
months and 48 months, respectively, after diagnoses of aggressive
gastric neuroendocrine tumors [12]. One patient had a large (16.0
× 4.5 cm) gastric carcinoid with multiple small gastric carcinoids
and metastatic duodenal gastrinomas. The gastric carcinoid was
metastatic to the liver and to multiple perigastric/periduodenal
lymph nodes. Surprisingly, the large gastric carcinoid did not in-
vade the muscularis propria. This patient had serum gastrin levels
ranging from 800 to 20,000 pmol/L. A second MEN-1 patient with
apparently normal gastrin levels developed a metastatic gastric
neuroendocrine carcinoma in addition to multiple gastric carci-
noids. This was the first report of a patient with MEN-1 who devel-
oped gastric carcinoids without ZES. Both of these patients’ tu-
mors had allelic losses at the MEN-1 gene locus in the 11q13
region.
In patients with ZES-MEN-1, ECL tumors may be included in
the spectrum of endocrine neoplasias, or they may be secondary to
other genetic influences in MEN-1. Cadiot et al. proposed that the
MEN-1 gene may be a recessive tumor suppressor gene [35]. They
found the loss of one allele of PYGM, a close probe to the MEN-1
locus, in ECL tumor DNA from a patient with ZES-MEN-1. This
genetic influence may be the transforming factor needed to de-
velop ECL tumors in patients with ZES-MEN-1.
Nearly all ZES-MEN-1 patients with ECL tumors have a history
of primary HPT, as did our two patients. Hypercalcemia contrib-
utes to hypergastrinemia and may be related to the development of
ECL tumors. One must also consider the converse—that ECL hy-
perplasia leads to increased histamine release, which can increase
the amount of basic fibroblast growth factor secreted by the endo-
crine cells. This growth factor is a strong parathyroid mitogen and
may be a significant factor in causing a high recurrence rate of hy-
perparathyroidism in MEN-1 patients [31].
The natural history of ECL tumors associated with hypergas-
trinemia is variable. Whereas some tumors progress to metastatic
disease, others follow a more benign course. Harvey reported two
patients with ECL tumors that regressed spontaneously [36]. Both
patients had hypergastrinemia associated with chronic atrophic
gastritis. We have previously reported two patients with atrophic
gastritis, hypergastrinemia, and multiple ECL tumors [7]. Both pa-
tients had evidence of invasion through the submucosa. Both of
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these patients underwent complete antrectomy and regional
lymphadenectomy. One patient also had a solitary liver metastasis,
which was resected; and the other had regional node involvement.
Following normalization of the serum gastrin level after antrec-
tomy, these patients were evaluated 4 to 6 months postoperatively.
In one patient the ECL tumors had completely regressed, and in
the other there were only multiple small foci of ECL tumors, which
had disappeared at the time of subsequent endoscopic examina-
tions. Neither patient has had a recurrence after 10 years of follow-
up. This is in contrast to the report by Wangberg et al. of a patient
with ECL tumors and atrophic gastritis that did not show any re-
gression following antrectomy with normalization of gastrin levels
[37]. In a review of five patients with ECL tumors and ZES-MEN-1,
Lehy et al. noted that two of the patients required total gastrectomy
and two others exhibited tumor progression [2].
Management
Endochromaffin-like tumors that are gastrin-dependent generally
behave in a benign fashion. They can be managed using conserva-
tive surgery with endoscopic surveillance and endoscopic excision
for tumors less than 1 cm. Larger tumors should be surgically ex-
cised. Antrectomy should be considered for patients with chronic
atrophic gastritis. In contrast, gastrin-independent ECL tumors of-
ten require gastric resection and lymph node dissection for cure.
The ECL tumors that develop in ZES-MEN-1 have posed a man-
agement dilemma because total gastrectomy became obsolete in
the treatment of ZES. Although antrectomy can be utilized in pa-
tients with atrophic gastritis to normalize serum gastrin, the proce-
dure has no role in ZES patients. Endoscopic surveillance and ex-
cision of tumors 1.0 cm or smaller has been recommended. Surgical
excision for tumors larger than 1 cm is currently recommended be-
cause the natural history of these larger tumors in ZES-MEN-1
patients is unknown. We are also unable to provide all patients with
normal gastrin levels following surgical intervention and want to
avoid a second operation to excise larger ECL tumors in a patient
with postoperative hypergastrinemia. In the future, with early di-
agnosis and normalization of serum gastrin levels, these large tu-
mors may be obsolete.
Tomassetti et al. reported resolution of ECL tumors in patients
with MEN-1 who had decreased gastrin after long-term treatment
(1 year) with somatostatic analogs [15]. Their results were consis-
tent with effects of gastrin levels on gastric carcinoids. However,
the question remained whether the somatostatin analogs had a di-
rect effect on the gastric carcinoid tumors. Our results provide an
answer. Because the patients were surgically treated to normalize
the gastrin, no somatostatin analogs were given to our patients.
There have been no previous reports of surgical attempts to nor-
malize the serum gastrin in ZES-MEN-1 patients who have con-
comitant ECL tumors. These two patients offered a unique oppor-
tunity to observe the effects of gastrin levels on multiple ECL
tumors in MEN-1 patients, providing their operations were suc-
cessful in eliminating the hypergastrinemia. We were hopeful that
this could be accomplished by the multifaceted procedure that we
have used for more than a decade in managing ZES-MEN-1 pa-
tients. Duodenotomy and either local or full-thickness wall excision
of all gastrinomas from pylorus to jejunum and regional node dis-
section are essential components of the operation. Furthermore,
any neuroendocrine tumors in the pancreatic head or uncinate pro-
cess must be detected and enucleated. The distal pancreatectomy is
needed to remove other potentially malignant or functional tumors
as well. During the past 20 years, we have utilized this procedure in
the surgical management of 36 ZES-MEN-1 patients who had no
evidence of liver metastases preoperatively or at the time of explo-
ration [38]. Duodenal gastrinomas were found in 89%, and they
were multiple in more than half (56%) of all patients. Metastatic
lymph nodes were excised in 37% of those with duodenal primary
gastrinomas. Pancreatic gastrinomas were detected and enucleated
in 36% of patients, nearly all from within the head or uncinate pro-
cess of the pancreas. Most of these tumors were present with con-
comitant duodenal gastrinomas. Only four patients (14%) had only
pancreatic gastrinomas as the source of their hypergastrinemia.
Other neuroendocrine tumors were found in the pancreatic neck,
body, or tail in all patients. Postoperatively, the serum gastrin levels
were decreased in all patients, and basal levels normalized in 69%,
as occurred in these two patients. All 36 of these patients had HPT
and had undergone previous parathyroidectomy or subtotal para-
thyroidectomy/thymectomy in conjunction with their abdominal
procedures (36%), as in case 1. All of these patients (except one
who had slightly elevated serum calcium levels) are currently nor-
mocalcemic. This includes five patients who underwent reopera-
tion for remnant recurrences during the 20-year period.
Normalization of serum gastrin resulting in decreased stimula-
tion of ECL cells may be a factor in our relatively low recurrence
rate of HPT in MEN-1 patients. Hyperplastic ECL cells have been
shown to be a rich source of basic fibroblast growth factor, which is
a strong parathyroid cell mitogen [39, 40]. In several reports of HPT
in MEN-1 patients, the recurrence rates ranged from 30% to 61%
after long-term follow-up after subtotal parathyroidectomy [41,
42]. In neither series was a consistent effort made to normalize the
serum gastrin level in patients with ZES.
Conclusions
We are the first to report the natural history of ECL tumors in
patients with ZES-MEN-1 (type 2 gastric carcinoids) whose gastrin
levels were normalized following surgical management. The reso-
lution of ECL tumors in ZES-MEN-1 patients who are normogas-
trinemic indicates that an elevated serum gastrin level is the pri-
mary initiator for the development of these tumors. The
normalization of serum gastrin levels can prevent the development
of aggressive, potentially life-threatening forms of ECL tumors.
Résumé. On a mis en évidence certaines tumeurs enterochromaffin-like
(ECL) chez des patients porteurs d’hypergastrinémie secondaire à une
gastrite atrophique chronique de l’estomac ou avec un syndrome de
Zollinger-Ellison associé à une néoplasie multiple endocrine de type 1
(ZES-MEN-1). Chez les patients porteurs de tumeurs ECL et de gastrite
atrophique, on peut voir une normalisation de la gastrinémie après
antrectomie accompagnée soit de résolution, soit de régression ou de
stabilisation des tumeurs ECL. A l’heure actuelle, l’histoire naturelle des
tumeurs ECL dans les syndromes ZES-MEN-1 avec normalisation de la
gastrinémie après résection n’est pas connue. Le but de cette étude a été de
déterminer l’évolution des tumeurs ECL chez des patients porteurs de
syndrome ZES-MEN-1 après normalisation des taux sériques de la
gastrine après résection de leur gastrinome. On a fait la preuve de tumeur
ECL chez deux patients porteurs de syndrome ZES-MEN-1, l’une
par biopsie, l’autre par évaluation endoscopique. Ces patients ont eu
une exploration chirurgicale comprenant une pancréatectomie distale,
l’énucléation de(s) tumeur(s) de la tête du pancréas, une duodénectomie
avec excision des tumeurs sous-muqueuses et une lymphadénectomie
péripancréatique. Les tumeurs gastriques ECL plus grandes que 1.0 cm
ont été excisées localement. Tous les patients ont été suivis à long terme par
une surveillance biochimique et endoscopique. Une normalisation de la
656 World J. Surg. Vol. 28, No. 7, July 2004
gastrinémie a été obtenue et maintenue suivant la résection du gastrinome
chez deux patients porteurs de syndrome ZES-MEN-1. Une surveillance
périodique pendant six ans a montré une résolution complète des tumeurs
ECL. Le développement des tumeurs ECL chez les patients porteurs de
syndrome ZES-MEN-1 est multifactoriel. Des études ont pu identifier une
influence génétique sur la croissance tumorale avec une perte d’hétérozygosité
au niveau du locus génétique MEN-1 pour les tumeurs ECL. La résolution
des tumeurs ECL chez des patients porteurs de syndrome ZES-MEN-1 qui
sont normogastrinémiques indiquent qu’un taux élevé de gastrine est
l’initiateur principal du développement de ces tumeurs. Ainsi, les déficits
génétiques et l’hypergastrinémie en sont les causes. La normalisation des
taux sériques de gastrine est critique dans la prévention des formes
agressives des tumeurs ECL.
Resumen. Está totalmente demostrada la existencia de tumores
enterocromafines (enterochromaffin-like) en pacientes con hipergastrinemia
secundaria a una gastritis atrófica crónica o a un sı́ndrome de Zollinger-
Ellison o a neoplasias encodrinas múltiples tipo 1 (ZES-MEN-1). En
pacientes con tumores ECL y gastritis atrófica, la normogastrinemia tras
antrectomı́a determina la desaparición, regresión o estabilización de los
tumores ECL. Se desconoce la evolución natural de los tumores ECL en
pacientes con sı́ndrome de ZES-MEN-1, una vez normalizada la gastrinemia,
tras la resección del gastrinoma. El objetivo de este trabajo fue averiguar
la evolución de los tumores ECL en pacientes con ZES-MEN-1, tras la
normalización de los niveles séricos de gástrica, consecutiva a la resección
del gastrinoma. Se presentan 2 pacientes con ZES-MEN-1; en uno se
constató por biopsia endoscópica la existencia de tumores ECL. A
continuación ambos casos fueron sometidos a una exploración quirúrgica
que comprendı́a: una pancreatectomı́a distal, enucleación de los tumores
de la cabeza del páncreas, duodenotomı́a y extirpación de los tumores
submucosos y linfadenectomı́a peripancreática. Los tumores ECL gástricos
de tamaño superior a 1.0 cm se extirparon “in situ”. Los pacientes fueron
sometidos a revisiones minuciosas durante largo tiempo, realizándose
pruebas bioquı́micas y estudios endoscópicos. Resultados: En los 2
pacientes con ZES-MEN-1 la resección del gastrinoma determinó una
normogastrinemia mantenida y la vigilancia periódica endoscópica durante
más de 6 años reveló la completa desaparición de los tumores ECL.
El desarrollo de los tumores similares a los enterocromafines (ECL) en
el ZES-MEN-1 tiene un origen multifactorial. Diversos estudios han
demostrado que el crecimiento de los tumores ECL está vinculado a la
pérdida de la heterocigosidad del gen MEN-1. La desaparición de tumores
ECL en pacientes con ZES-MEN-1 que han normalizado su gastrinemia,
demuestra que los niveles elevados de gastrina son los primeros y más
precoces inductores del desarrollo de estos tumores. De ahı́, que tanto las
alteraciones genéticas como la hipergastrinemia hayan de ser consideradas
como agentes causales. La normalización sérica de los niveles de gastrina
es fundamental para prevenir el desarrollo de formas agresivas de tumores
enterocromafines.
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